Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Corcept Therapeutics Incorporated”

120 pharma patents match "Corcept Therapeutics Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 3 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "Corcept Therapeutics Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “Corcept Therapeutics Incorporated” · 30,257 patents in full index Clear search

  1. US 11173165

    Optimizing mifepristone levels for Cushing's patients

    Corcept Therapeutics Incorporated · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  2. US 11103514

    Treatment of muscular dystrophy

    Corcept Therapeutics Incorporated · Granted Aug 31, 2021 · Expires Aug 26, 2041

    granted

  3. US 11073523

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted

  4. US 11058670

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted

  5. US 11045482

    Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

    Corcept Therapeutics Incorporated · Granted Jun 29, 2021 · Expires Jun 24, 2041

    granted

  6. US 10980797

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Corcept Therapeutics Incorporated · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  7. US 10973813

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  8. US 10946005

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  9. US 10898478

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted

  10. US 10881660

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted

  11. US 10842800

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  12. US 10842801

    Optimizing mifepristone absorption

    Corcept Therapeutics Incorporated · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  13. US 10828280

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted

  14. US 10787449

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  15. US 10780097

    Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  16. US 10660904

    Optimizing mifepristone levels for cushing's patients

    Corcept Therapeutics Incorporated · Granted May 26, 2020 · Expires May 21, 2040

    granted

  17. US 10646474

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted May 12, 2020 · Expires May 7, 2040

    granted

  18. US 10610534

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  19. US 10604807

    Methods for diagnosing and assessing treatment for Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Mar 31, 2020 · Expires Mar 26, 2040

    granted

  20. US 10568880

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted

  21. US 10500216

    Optimizing mifepristone absorption

    Corcept Therapeutics Incorporated · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  22. US 10495650

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted

  23. US 10456392

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  24. US 10449178

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.